Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

Enrique Grande • 29 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Atezolizumab Checkpoint Inhibitors
IMvigor130

Enrique Grande, MD, from the MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the results of his late-breaking abstract at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. The Phase 3 IMvigor130 trial (NCT02807636) evaluated the efficacy and safety of atezolizumab alone or in combination with platinum-based chemotherapy (PBC) vs. a placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma.

More from Enrique Grande

Current care and biomarker needs in first-line metastatic urothelial cancer
1:47
Current care and biomarker needs in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel strategies for the management of metastatic urothelial cancer
1:28
Novel strategies for the management of metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel ADCs for bladder cancer beyond enfortumab vedotin
1:57
Novel ADCs for bladder cancer beyond enfortumab vedotin
Enrique Grande • 19 Oct 2025
Evolving standards in first-line metastatic urothelial cancer
1:11
Evolving standards in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals